UK-based Alesi Surgical has received approval from the US Food and Drug Administration (FDA) of the use of its Ultravision system during surgical procedures.

The system allows improved visibilty during abdominal keyhole (laparoscopic) surgery, by clearing the vapour and particulate matter produced by surgical cutting instruments.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Equipped with electrostatic technology, the system generates a small, low-energy electrostatic charge.

"Our new Ultravision Trocar product in Europe integrates the benefits of Ultravision into a pen-like access device."

Alesi Surgical managing director Dominic Griffiths said: "Commercially the US represents approximately fifty% of the global medical device market and so it is difficult to overstate the importance of this for the company."

The electrostatic precipitation process of the device involves the movement of its negatively charged gas ions towards the positively charged patient tissue in the abdominal cavity, resulting in a collision which clears the water vapour and particulate matter.

Griffiths added: “Gaining FDA approval for Ultravision allows us to continue the progress and development in the US market.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

"This is the next step after launching our new Ultravision Trocar product in Europe which integrates the benefits of Ultravision into a pen-like access device, used in over seven million abdominal keyhole procedures performed annually, worldwide."

The system also reduces the amount of cold, dry carbon dioxide gas used to create a working space inside the abdomen during the keyhole procedure.

This aids in decreasing the post-surgical pain and enchanced recovery time for the patient, which are caused due to use of excessive carbon dioxide.

Alesi Surgical was established in 2009 as a spin out from the Welsh Institute of Minimally Invasive Surgery.